news
New evidence on variability of plasma miR-122 published with contribution of TAmiRNA
A short communication published in the British Journal of Clinical Pharmacology re-evaluates the inter- and intra-individual variability of circulating miR-122 in healthy volunteers, using small RNA sequencing generated on TAmiRNA's miND workflow (Javid et al., 2026, doi:10.1002/bcp.70836). Background MicroRNA-122 (miR-122) is a liver-enriched circulating microRNA and one of the most extensively studied candidate biomarkers for drug-induced liver injury (DILI). A 2019 evaluation by [...]
TAmiRNA Joins Six European RNA Specialists to Launch the European RNA Alliance
As a founding member of ERA, TAmiRNA positions itself as the innovative driving force behind RNA biomarker development in Europe — combining novel biomarker products with premier research services in cell-free RNA and EV/exosome analysis. Vienna, Austria — September 8, 2026 TAmiRNA is proud to announce that it has joined six other independent European RNA companies — Anemocyte, Genevia Technologies, Immagina Biotechnology, Lexogen, [...]
TAmiRNA is a Silver Sponsor at the D-A-CH EV Meeting 2026 in Erlangen
From September 28–30, 2026, the D-A-CH EV Meeting 2026 will take place at the Hörsaalzentrum of the Medical Faculty, University Hospital Erlangen — the first joint annual meeting of the German, Austrian and Swiss societies for extracellular vesicles (GSEV, ASEV and SwissEV). Under the motto "Extracellular Vesicles: Communication Across Barriers," around 300 to 350 international scientists from the EV field will gather in [...]
TAmiRNA at the 5th MC/WG Meeting of COST Action AtheroNET in Prague
From September 2–4, 2026, the COST Action AtheroNET (CA21153) network will gather for its 5th Management Committee and Working Group meeting at the University of Chemical Technology in Prague. AtheroNET is supported by COST (European Cooperation in Science and Technology) and connects European research groups working on new approaches to understanding and diagnosing atherosclerosis. The three-day programme promises intensive scientific exchange: from a [...]
TAmiRNA CEO Dr. Matthias Hackl to Lecture on microRNA Biomarker Development at Jyväskylä Summer School 2026
Our CEO Dr. Matthias Hackl, a leading expert in microRNA biomarker discovery, small RNA sequencing, and IVD development, has been invited as a lecturer at this year's Jyväskylä Summer School at the University of Jyväskylä, Finland. As part of the course BIO1: MicroRNA Biology and Function (4–6 August 2026), he will join an international team of experts from Helsinki, Kuopio, and Jyväskylä to [...]
Circulating microRNAs Reveal Molecular Effect of Zoledronic Acid on Tendon-to-Bone Healing
New publication in the American Journal of Sports Medicine, co-authored by TAmiRNA Retears remain a common complication after arthroscopic rotator cuff repair. A recent study by researchers from the AUVA Trauma Center Vienna-Meidling, the Ludwig Boltzmann Institute for Traumatology, the Austrian Cluster for Tissue Regeneration, and TAmiRNA now sheds light on the molecular mechanism behind a promising augmentation strategy: a single intraoperative dose [...]
Why Spike-ins Are the Key to Reproducible Small RNA-seq Data
Reproducibility is one of the biggest challenges in small RNA sequencing – and at the same time one of the most critical requirements for valid biomarker studies. Whether you are comparing data across batches, running multi-laboratory studies, or working with disease cohorts that show shifts in global RNA content: without an external reference, there is no reliable anchor to make your data truly [...]
A New Milestone in EV-Based Therapies Research
A major hurdle in EV-based therapies is the "yield gap" — standard lab protocols simply cannot produce the volume of extracellular vesicles (EVs) required for clinical applications. However, scale-up could impact the quality and potency of therapeutic EVs. In our latest co-authored study published in 𝗦𝘁𝗲𝗺 𝗖𝗲𝗹𝗹𝘀 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲, the teams at Exosomica, the Innovative Medicine Centre, the University of Latvia, alongside TAmiRNA [...]
New publication in Biomaterials
Huge congrats to Cansu Gorgun and the teams at Royal College of Surgeons in Ireland (RCSI) and Trinity College Dublin on their new publication in Biomaterials! This study is a fascinating look at how we can "train" macrophages to do two things at once. By reprogramming their metabolism, the team produced hybrid M1/M2 extracellular vesicles — a "dual-action" package that combines pro-inflammatory and [...]
TAmiRNA @ RNA Leaders Europe Conference
Vienna, Austria – 17.-19. March 2026 TAmiRNA is pleased to announce that CEO/CSO Matthias Hackl and Head of R&D Teresa Krammer will attend the upcoming RNA Leaders Europe Conference, one of the leading industry events dedicated to RNA therapeutics, innovation, and translational research. RNA Leaders Europe brings together key stakeholders from academia, biotech, pharma, and technology providers to discuss the latest scientific advances, [...]

















